Pfizer Inc. $PFE Shares Bought by Wesbanco Bank Inc.

Key Points

• Wesbanco Bank Inc. increased its shareholding in Pfizer by 10.6% during the 2nd quarter, owning a total of 214,238 shares valued at approximately $5.19 million.
• Pfizer's quarterly earnings showed an EPS of $0.78, surpassing estimates of $0.58, with revenues of $14.65 billion for the quarter, a 10.3% increase year-over-year.
• The company declared a quarterly dividend of $0.43 per share, resulting in a 7.2% annualized yield and a payout ratio of 91.49%.

Wesbanco Bank Inc. raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 10.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 214,238 shares of the biopharmaceutical company's stock after buying an additional 20,474 shares during the period. Wesbanco Bank Inc.'s holdings in Pfizer were worth $5,193,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PFE. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. purchased a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $30,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 3.8%

PFE stock opened at $23.91 on Friday. The firm has a market cap of $135.94 billion, a PE ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm's 50 day moving average price is $24.79 and its 200-day moving average price is $24.28. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Jefferies Financial Group upped their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America upped their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and an average price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.